Affiliation:
1. Department of Medical Oncology and Hematology University Hospital Zurich Zurich Switzerland
2. Institute of Medical Virology University of Zurich Zurich Switzerland
3. Department of Infectious Diseases and Hospital Epidemiology University Hospital Zurich University of Zurich Zurich Switzerland
4. National Specialized Hospital for Hematological Diseases Sofia Bulgaria
Abstract
SummaryAllogeneic haematopoietic cell transplantation (allo‐HCT) recipients exhibit an increased risk of COVID‐19, particularly in the early post‐transplant phase, due to insufficient vaccine responses. This retrospective study investigated the incidence of SARS‐CoV‐2 infection in allo‐HCT recipients who received tixagevimab/cilgavimab pre‐exposure prophylaxis (T/C PrEP) compared to those who did not. Logistic regression, adjusted for sex, age, SARS‐CoV‐2 vaccination status and immunosuppressive treatment, revealed a significant reduction in the likelihood of SARS‐CoV‐2 infection risk with T/C PrEP (adjusted odds ratio aOR = 0.26 [0.07, 0.91]). These findings suggest the potential efficacy of monoclonal antibody PrEP in protecting this vulnerable patient population from COVID‐19.